SCHEMBL308415

SCHEMBL308415

CCOc1cc(C(=O)O)cc2c1c(C)cn2C1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.40
ACACA Q13085 1/20 0.40
TSHR P16473 2/20 0.40
POLB P06746 3/20 0.38
ALOX15 P16050 1/20 0.38
HTT P42858 1/20 0.38
GLA P06280 1/20 0.37
ALDH1A1 P00352 1/20 0.36
CASP6 P55212 1/20 0.36
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.35
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
NSD2 O96028 1/20 0.34
MAPT P10636 1/20 0.34
RECQL P46063 1/20 0.34
KMT2A Q03164 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL309739 0.87 POLB (0.44) TSHRPOLBALOX15HTTGLA
SCHEMBL4782664 0.86 TSHR (0.37) TSHRPOLBALOX15HTTGLA
SCHEMBL309592 0.86 ACACB (0.49) ACACBACACATSHRHTTKMT2A
SCHEMBL309221 0.85 TSHR (0.40) TSHRPOLBALOX15HTTALDH1A1
SCHEMBL308834 0.81 TSHR (0.35) TSHRPOLBALOX15HTTALDH1A1
SCHEMBL309106 0.80 HSD17B2 (0.44) ACACBACACAPOLBHTTALDH1A1
SCHEMBL4782659 0.79 GLA (0.38) POLBGLAALDH1A1GAASMN1; SMN2
SCHEMBL308422 0.77 TSHR (0.44) TSHRPOLBALOX15HTTGLA
SCHEMBL308796 0.74 RXFP1 (0.38) GLAALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL309447 0.74 GLA (0.34) GLAALDH1A1NPSR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2111406-B1 SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS MERCK SHARP & DOHME (US) 2012-10-24 EP disclosed
US-8093389-B2 e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases MERCK SHARP & DOHME CORP. (US) 2012-01-10 US disclosed
EP-2111406-A1 SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS Merck & Co., Inc. (US) 2009-10-28 EP disclosed
WO-2008088688-A1 SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS MERCK & CO., INC. (US) 2008-07-24 WO disclosed
WO-2008088689-A1 SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS MERCK & CO., INC. (US) 2008-07-24 WO disclosed
US-20080171761-A1 Substituted spirochromanone derivatives MERCK SHARP & DOHME LLC 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171761-A1 Substituted spirochromanone derivatives CBR3, CBR1, CNKSR1 ACACB 713/4885ACACA 470/4885TSHR 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.